I am writing on behalf of the OCTAVE consortium to express our great sadness at the loss of such a wonderful colleague. We came together early in 2021, as a group of clinicians, scientists and trialists with one purpose; to work together to perform research that would answer the questions that were critically important to immunocompromised patients concerning the value of COVID 19 vaccines. Paul joined the consortium from the start, and this was when many of us met him for the first time (albeit only on videoconferences). In the relatively short time that we had the privilege to work with Paul, it was clear that he was a dedicated and compassionate doctor and a warm and generous individual. He was also a highly talented researcher bringing his in-depth knowledge of post-transplant immunity to the OCTAVE suite of clinical trials, which have made important contributions to the UK COVID 19 vaccination policies for vulnerable patients. We will continue to honour Paul’s legacy as we disseminate the results of this research in scientific journals and public communications. He is greatly missed, his humanity and intellect hugely valued. His family remains in our thoughts.